Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

Study limitation reported by the research below: “The comparator is insulin glargine U100 only — no comparison to GLP-1 monotherapy or other basal-bolus regimens was made.”